Brompheniramine / Codeine / Phenylephrine Dosage
Medically reviewed on January 15, 2018.
Applies to the following strengths: 1.33 mg-6.33 mg-3.33 mg/5 mL; 4 mg-10 mg-7.5 mg/5 mL; 4 mg-10 mg-10 mg/5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Cough and Nasal Congestion
Brompheniramine/codeine/phenylephrine 4 mg-10 mg-10 mg/5 mL oral liquid:
5 mL orally every 4 to 6 hours not to exceed 30 mL daily
Brompheniramine/codeine/phenylephrine 1.33 mg-6.33 mg-3.33 mg/5 mL oral liquid:
15 mL orally every 4 to 6 hours not to exceed 90 mL daily
-Liquid preparations should be measured with an accurate milliliter measuring device.
Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.
Renal Dose Adjustments
Use with caution
Liver Dose Adjustments
Use with caution
Elderly: Use with caution generally starting at the lower end of the dosing range
The US FDA recommends against use of codeine-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.
Consult WARNINGS section for additional precautions.
US Controlled Substance: Schedule V
Data not available
-Take orally with or without food
-Oral measuring devices should be used to ensure accuracy in dosing; a household teaspoon should not be considered an accurate measuring device
-Protect from moisture and light
-Patients who are ultra-rapid metabolizers of codeine due to a CYP450 2D6 polymorphism, will convert codeine more rapidly and completely to morphine resulting in unexpectedly high morphine levels, which may be life-threatening.
-Codeine use is contraindicated in the postoperative period in pediatric patients who have undergone tonsillectomy and/or adenoidectomy.
-Cardiovascular: Monitor for signs of hypotension, especially in those whose blood pressure is compromised
-Respiratory: Monitor for respiratory depression
-Gastrointestinal: Monitor for constipation and decreased bowel motility
-Patients should be monitored for the development of addiction, abuse, or misuse.
-Patients should understand that codeine use can result in addiction, abuse, and misuse.
-Patients should understand risks of life-threatening respiratory depression and when this risk is greatest; patients should be aware that a genetic mutation may result in greater codeine toxicity in some patients; breastfed infants of women who have this genetic mutation are also at risk.
-Women who are breastfeeding, pregnant, or planning to become pregnant should speak to their healthcare provider before using this product.
-This drug may cause drowsiness, dizziness, or impair thinking or motor skills; patients should avoid driving or operating machinery while taking this drug
-Concomitant use of alcohol, sedatives, and tranquilizers may increase drowsiness; patients should avoid alcohol and consult with their healthcare provider regarding concomitant use of other CNS depressants.
More about brompheniramine/codeine/phenylephrine
- Brompheniramine/codeine/phenylephrine Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 1 Review
- Drug class: upper respiratory combinations